Safety and tolerance of zolpidem in the treatment of disturbed sleep: A post-marketing surveillance of 16 944 cases

International Clinical Psychopharmacology

Volumn 13, Issue 4, 1998, Pages 157-167

  Hajak, G ^a   Bandelow, B ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

Adverse events; Hypnotics; Imidazopyridine; Insomnia; Post marketing surveillance; Zoldipem

Indexed keywords

BARBITURIC ACID DERIVATIVE; DIAZEPAM; DOXEPIN; FLUNITRAZEPAM; HYPNOTIC AGENT; LORMETAZEPAM; METHADONE; NITRAZEPAM; OXAZEPAM; PROMETHAZINE; ZOLPIDEM;

ADOLESCENT; ADULT; AGED; AGITATION; ARTICLE; CLINICAL TRIAL; DRUG SAFETY; FEMALE; GERMANY; HEADACHE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALAISE; MALE; MULTICENTER STUDY; NAUSEA; NIGHTMARE; OUTPATIENT; PARANOIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; VERTIGO;

EID: 0031823398     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004850-199807000-00002     Document Type: Article

References (48)

1. Allain H, Delahaye Ch, Le Coz F, Blin P, Decombe R, Martinet JP (1991). Post-marketing surveillance of zopiclone in insomnia: analysis of 20513 cases. Sleep 14:408-413.
2. Allain H, Monti J (1997). General safety profile of Zolpidem: safety in elderly, overdose and rebound effects. Eur Psychiatry 12 (Suppl. 2):21S-29S.
3. Allain H, Rahola JG (1996). Switch to Zolpidem after chronic benzodazepine use. In: Zolpidem: an update of its pharmacological properties and therapeutic place in the management of insomnia. (H Freeman, AJ Puech, T Roth, eds). Paris: Elsevier. pp. 175-182.
4. Backhaus J, Müller-Popkes K, Hajak G, Voderholzer U, Venegas M, Riemann D, Hohagen F (1996). Neue ergebnisse zur prävalenz von insomnien und ihrer behandlung in der hausarztpraxis. Psycho 22:631-637.
5. Benavides J, Abadie P, Baron JC, Scatton B (1996). In vivo interaction of Zolpidem with ω (benzodiazepine) site subtypes. In: Zolpidem: an update of its pharmacological properties and therapeutic place in the management of insomnia. (H Freeman, AJ Puech, T Roth, eds). Paris: Elsevier. pp. 33-44.
6. A receptor subtypes and the mechanism of action of Zolpidem. In: Zolpidem: an update of its pharmacological properties and therapeutic place in the management of insomnia. (H Freeman, AJ Puech, T Roth, eds). Paris: Elsevier. pp. 21-32.
7. Besset A, Tafti M, Villemin E, Borderies P, Billiard M (1995). Effects of Zolpidem on the architecture and cyclical structure of sleep in poor sleepers. Drugs Exp Clin Res 21:161-169.
8. Bundesinstitut für Arzneimittel und Medizinprodukte. Bericht über unerwünschte Arzneitmittelwirkungen des Bundesinstitutes für Arzneimittel und Medizinprodukte. Deutschland.
9. Curran HV (1991). Benzodiazepines, memory and mood: a review. Psychopharmacology 105:1-8.
10. Declerck AC, Bisserbe JC (1997). Short-term safety profile of Zolpidem: objective measures of cognitive effects. Eur Psychiatry 12 (Suppl. 1):15S-20S.
11. Folkard S (1981). Shiftwork and performance in 24-hour workday: Proceedings of a symposium on variations in sleep-work schedules, DMSS Publication Number (NIOSH). Washington DC: US Government Printing Office. pp. 81-127.
12. Freeman H, Puech AJ, Roth T, eds (1996). Zolpidem: an update of ist pharmacological properties and therapueutic place in the management of insomnia. Amsterdam: Elsevier.
13. Gallup Organization (1991). Sleep in America: a national survey of US adults. Princeton, NJ: Gallup.
14. Ganzoni E, Santoni JP, Chevillard V, Sebille M, Mathy B (1995). Zolpidem in insomnia: a 3 year post-marketing surveillance study in Switzerland. J Int Med Res 23:61-73.
15. Hajak G, Rüther E (1995). Insomnie. Berlin: Springer,.
16. Haldemann R, Good M, Holsboer-Trachsler E (1996). Epidemiological study on sleep disorders in patients in Schwiss general practice. Schweizer Rundschau Medizin (Praxis) 85:1656-1662.
17. Herrmann WM, Kubicki St, Boden S (1993). Pilot controlled double-blind study of the hypnotic effects of Zolpidem in patients with chronic 'learned' insomnia: psychometric and polysomnographic evaluation. J Int Med Res 21:306-322.
18. Hoehns JD, Perry PJ (1993). Zolpidem: a nonbenzodiazepine hypnotic for treatment of insomnia. Clin Pharm 12:814-828.
19. Hohagen F, Rink K, Käppler C, Schramm E, Riemann D, Weyerer S, Berger M (1993). Prevalence and treatment of insomnia in general practice. Eur Arch Gen Psychiatry Clin Neurosci 242:329-336.
20. Janson C, Gislason T, De Backer W, Plaschke P, Björnsson E, Hetta J, et al. (1995). Prevalence of sleep disturbances among young adults in three European countries. Sleep 18:589-597.
21. Kales A, Kales JD (1984). Evaluation and treatment of insomnia. Oxford: Oxford University Press.
22. Kripke DF, Ancoli-Israel S, Fell RL, Mason WJ, Lauber MR, Kaplan O (1991). Health risk of insomnia. In: Sleep and health risk. (JH Peter, T Penzel, T Podszus, P von Wichert, eds). Berlin: Springer. pp. 547-554.
23. Kryger M, Salvà P (1996). Polysomnographic comparisons of Zolpidem and benzodiazepines healthy volunteers and patients with insomnia. In: Zolpidem: an update of its pharmacological properties and therapeutic place in the management of insomnia. (H Freeman, AJ Puech, T Roth, eds). Paris: Elsevier. pp. 141-148.
24. Lader MH, Hindmarch I (1996). Memory, psychomotor and cognitive functions after treatment with Zolpidem. In: Zolpidem: an update of its pharmacological properties and therapeutic place in the management of insomnia. (H Freeman, AJ Puech, T Roth, eds). Paris: Elsevier. pp. 59-72.
25. Langtry HD, Benfield B (1990). Zolpidem. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential. Drugs 40:291-313.
26. Lister RG (1985). The amnesic action of benzodiazepines in man. Neurosci Biobehav Rev 9:87-94.
27. National Sleep Foundation (1996). The pharmacological management of insomnia: a white paper of the National Sleep Foundation. Washington DC: National Sleep Foundation.
28. Ohayon M (1996). Epidemiological study on insomnia in the general population. Sleep 19:7-15.
29. Palminteri R, Narbonne G (1988). Safety profile of Zolpidem. In: Imidazopyridines in sleep disorders. LERS monograph series, Vol. 6. (JP Sauvanet, SZ Langer, PL Morselli, eds). New York: Raven. pp. 351-361.
30. Parkes JD (1985). Sleep and its disorders. Philadelphia: Saunders.
31. Parrino L, Terzano MG (1996). Polysomnographic effects of hypnotic drugs. A review. Psychopharmacology 126:1-16.
32. Parson M (1986). Fits and other couses of loss of consciousness while driving. Quarterly J Med 227:295-303.
33. Priest RG, Cluydts R (1996). Subjective assessment of the efficacy of Zolpidem. In: Zolpidem: an update of its pharmacological properties and therapeutic place in the management of insomnia. (H Freeman, AJ Puech, T Roth, eds). Paris: Elsevier. pp. 161-174.
34. Priest RG, Terzano MG, Parrino L, Boyer P (1996). Efficacy of Zolpidem in insomnia. Eur Psychiatry 2 (Suppl. 1):5-14.
35. Pringuey D, Sallière D (1996). Tolerability and safety of Zolpidem. In: Zolpidem: an update of its pharmacological properties and therapeutic place in the management of insomnia. (H Freeman, AJ Puech, T Roth, eds). Paris: Elsevier. pp. 195-214.
36. Roehrs T, Merlotti L, Zorick F, Merlotti L, Zorick F, Roth T (1994). Sedative, memory and performance effects of hypnotics. Psychopharmacology 116:130-134.
37. Roger M, Frattola L (1996). Subjective efficacy of Zolpidem in the elderly. In: Zolpidem: an update of its pharmacological properties and therapeutic place in the management of insomni. (H Freeman, AJ Puech, T Roth, eds). Paris: Elsevier. pp. 183-194.
38. Salvà P, Costa J (1995). Clinical pharmacokinetics and pharmacodynamics of Zolpidem. Clin Pharmacokinet 29:142-153.
39. Sauvanet JP, Langer SZ, Morselli PL, eds (1988). Imidazopyridines in sleep disorders, LERS monograph Series Volume 6. New York: Raven.
40. Schlich D, L'Heritier CL, Coquelin JP, Attali P (1991). Long-term treatment of insomnia with Zolpidem: a multicentre general practitioner study of 107 patients. J Int Med Res 19:271-279.
41. Simen S, Hajak G, Schlaf G, Westenhöfer J, Rodenbeck A, Bandelow B, et al. (1995). Chronic sleep complaints. Results of a representative survey in Germany. Nervenarzt 66 686-695.
42. Stephens S, Sanger DJ (1996). In: Zolpidem: an update of its pharmacological properties and therapeutic place in the management of insomnia. (H Freeman, AJ Puech, T Roth, eds). Paris: Elsevier.
43. Undén M, Roth Schechter B (1996). Next days effect after nightime treatment with Zolpidem: a review. Eur Psychiatry 11 (Suppl. 1):21S-30S.
44. Üstün TB, Privett M, Lecrubier Y, Weiller E, Simon G, Korten A, et al. (1996). Form, frequency and burden of sleep problems in general health care: a report from the WHO Collaborative Study on Psychological Problems in General Health Care. Eur Psychiatry 11 (Suppl. 1):5S-10S.
45. Üstün TB, Sartorius N (1995). Mental illness in general health care: an international study. Geneva: Wiley.
46. Vogel G, Poirrier R (1996). Studies of effects following discontinuation of Zolpidem treatment. In: Zolpidem: an update of its pharmacological properties and therapeutic place in the management of insomnia. (H Freeman, AJ Puech, T Roth, eds). Paris: Elsevier. pp. 149-160.
47. Walsh J, Roehrs T, Declerck AC (1996). Polysomnographic studies of the effect of Zolpidem in patients with insomnia. In: Zolpidem: an update of its pharmacological properties and therapeutic place in the management of insomnia. (H Freeman, AJ Puech, T Roth, eds). Paris: Elsevier. pp. 129-140.
48. World Health Organization (1978). Manual of the International Statistical Classification of Diseases, Injuries and Causes of Death. World Health Organization, Geneva.